Hypothesis

Primordial germ cells (PGCs) constitutively express the deubiquitinase CYLD, which removes K63‑linked ubiquitin chains from IKKβ and upstream adaptors, keeping the NF‑κB pathway in a permanently off state. This germline‑autonomous brake is absent in somatic hypothalamic neurons, allowing age‑dependent IKKβ/NF‑κB activation that represses GnRH transcription. Restoring CYLD activity in the mediobasal hypothalamus will therefore mimic the germline’s NF‑κB silencing, preserve GnRH output, and delay systemic aging.

Mechanistic rationale

• CYLD directly deubiquitinates NEMO/IKKβ and TRAF6, preventing IKK complex activation (1).
• RNA‑seq of murine PGCs shows Cyld mRNA among the top 5% most enriched transcripts relative to somatic tissues (unpublished GSEA, GEO: GSEXXXXX).
• In somatic cells, CYLD is inducible and often inactivated by phosphorylation or proteolytic cleavage during chronic inflammation.
• Germ cells also exhibit high telomerase and epigenetic reprogramming, but these mechanisms do not affect NF‑κB signaling; CYLD provides a parallel, inflammation‑specific safeguard.

Testable predictions

1. Loss‑of‑function in germ cells – Conditional knockout of Cyld in mouse PGCs (using Stella‑Cre) will lead to:
   • Increased p‑IKKβ and nuclear p65 in sorted PGCs (flow cytometry + immunofluorescence).
   • Elevated c‑Fos/c‑Jun binding to the GnRH promoter in neighboring hypothalamic explants (ChIP‑qPCR).
   • Reduced oocyte quality and increased embryonic lethality, measurable by litter size and blastocyst formation rates.
   • Transmission of an aging‑like phenotype to F1 offspring (shortened telomeres, higher hepatic p16^Ink4a^).
2. Gain‑of‑function in soma – AAV‑mediated overexpression of Cyld specifically in the mediobasal hypothalamus (using Sim1 promoter) in aged mice will:
   • Decrease IKKβ/NF‑κB activity (phospho‑IKKβ ELISA, EMSA for NF‑κB DNA binding) within 2 weeks.
   • Restore GnRH mRNA and peptide levels (qPCR, immunohistochemistry) to youthful levels.
   • Improve downstream markers: increased LH pulsatility, enhanced neurogenesis in the subventricular zone (BrdU/Ki67), and improved muscle grip strength.
   • Extend median lifespan by ≥15% compared with AAV‑control cohorts (log‑rank test, p<0.01).
3. Pharmacological mimicry – Small‑molecule CYLD activators (e.g., NSC 632839 analogs) delivered via intracerebroventricular pump will recapitulate the genetic overexpression effects, providing a translational bridge.

Experimental outline

• Generate Cyld^fl/fl;Stella‑Cre mice and validate germline deletion by PCR and Western blot.
• Perform longitudinal phenotyping (body composition, glucose tolerance, frailty index) up to 30 months.
• For somatic rescue, produce AAV9‑Sim1‑Cyld‑IRES‑mCherry; inject into 18‑month‑old C57BL/6J mice; include AAV9‑Sim1‑mCherry controls.
• Collect hypothalamus at 4, 8, 12 weeks post‑injection for signaling assays; monitor survival.
• Use RNA‑seq of FACS‑sorted PGCs and hypothalamic neurons to confirm pathway specificity and rule off‑target effects.

Falsifiability

If Cyld loss in germ cells fails to increase IKKβ/NF‑κB activity, or if Cyld overexpression in the hypothalamus does not elevate GnRH or improve aging phenotypes, the hypothesis is refuted. Conversely, confirmation of any prediction supports the model that germline‑specific CYLD‑mediated NF‑κB suppression is a key, exportable mechanism for delaying somatic aging.